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Abstract 
The production of interleukin-5 and eosinophil cationic protein (ECP) in the nasal cavity was examined in 24 patients with 
rhinitis who were allergic to the house dust mite. During a double-blind placebo-controlled cross-over study, fluticasone 
propionate aqueous nasal spray (200 tzg) was administered twice daily for 2 weeks. After four basal nasal lavages provocation 
with house dust mite extract was performed and nasal lavages were collected every hour for 9.5 h. Interleukin-5 was present in 
detectable amounts in nasal lavages from patients allergic to house dust mite. Nasal challenge with house dust mite extract 
caused immediate nasal symptoms and increased levels of interleukin-5. Between 3.5 and 8.5 h after the challenge symptoms 
recurred and interleukin-5 levels increased, reflecting a late phase reaction. Eosinophil cationic protein, a marker of activated 
eosinophils, was released between 6.5 and 9.5 h after challenge. Treatment with fluticasone propionate (as an aqueous nasal 
spray) significantly decreased the evoked interleukin-5 and ECP levels in the late phase reaction. This response was correlated 
with an improved symptom score. This could indicate that the number and activity of eosinophils are increased uring the late 
phase allergic reaction, a response that is inhibited by corticosteroids. 
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I. Introduction 
Human allergen-induced responses in the nose are 
used as a model for allergic inflammation (Gerth van 
Wijk et al., 1992; Naclerio et al., 1983). After provoca- 
tion with antigen, mediators, such as prostaglandin D 2, 
leukotriene E4, tryptase and histamine, are released 
during the so-called early allergic reaction, which causes 
sneezing, nasal blockage and rhinorrhoea. After a qui- 
escent period, a late allergic reaction occurs and symp- 
toms recur (Iliopoulos et al., 1990; Naclerio et al., 
1983; Pelikan, 1978). Studies on human nasal late 
responses have shown an influx of eosinophils and an 
increase in the content of eosinophil cationic protein 
* Corresponding author. Department of Pharmacology, Faculty of 
Medicine, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR 
Rotterdam, Netherlands. Tel. (+31) 10 4087544, fax (+31) 10 
4366839. 
0014-2999/95/$09.50 © 1995 Elsevier Science B.V. All rights reserved 
SSDI 0014-2999(95)00049-6  
(ECP) in nasal fluids 3-11 h after challenge. The 
presence of mononuclear cells in lavage fluid during 
the late responses has also been recognized (Iliopoulos 
et al., 1990). Several studies have suggested a role for 
cytokines, particularly granulocyte-macrophage colony- 
stimulating factor (GM-CSF), interleukin-3 and inter- 
leukin-5, in the initiation of allergic inflammation. 
These cytokines promote the survival and activation of 
eosinophils in vitro, enhance adhesion to microvascular 
endothelial cells in vitro and induce eosinophilia in 
vivo. Mosmann and colleagues described two classes of 
T helper lymphocytes on the basis of their profile of 
cytokine release. THI cells produce interleukin-2, inter- 
leukin-3, interferon-'/and GM-CSF but no interleukin- 
4 or interleukin-5, whereas Tr~ 2 clones produce inter- 
leukin-3, interleukin-4, interleukin-5, interleukin-10 
and GM-CSF but no interleukin-2 or interferon-,/ 
(Mosmann et al., 1986). However, the exact cells from 
which GM-CSF, interleukin-4 and interleukin-5 are 
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released remain to be determined, because other stud- 
ies have shown that mast cells also produce inter- 
leukin-4 and interleukin-5 (Wodnar-Filipowicz et al., 
1989) whereas eosinophils may produce GM-CSF and 
interleukin-5. 
In our study, the nasal challenge model developed 
by Naclerio et al. (1983) was used to correlate clinical 
symptoms and the release of biochemical markers uch 
as interleukin-5 and ECP and to establish whether 
these markers are formed predominantly in the early 
or late phase of the allergic process in patients with 
allergic rhinitis. Furthermore, the effect of fluticasone 
propionate, a new and potent corticosteroid, on the 
levels of interleukin-5, ECP and on symptom scores 
after nasal challenge with allergen was investigated. 
2. Materials and methods 
2.1. Patients 
This study was performed with 24 patients (11 
women and 13 men, aged 21-50 years, mean: 34 years). 
All patients had a history of perennial rhinitis and a 
skin reaction to extract of house dust mite as an 
inclusion criterion. The skin reaction was rated as at 
least one '+ '  sign in response to 0.3 or 3 biological 
units (BU) /ml  extract, according to the standardized 
plus-sign scoring system. Six of the 24 patients were 
also allergic to grass pollen or animal dander. The 
nasal lavage experiments were performed in January-  
August to minimize exposure to house dust mite. The 
patients with a concomitant pollen allergy were tested 
outside the pollen season. None of the patients allergic 
to animals had pets in their home. Anti-histaminic 
drugs were withdrawn 72 h before testing. The antihis- 
tamine astemizole, topical corticosteroids, cromogly- 
cate or nedocromil were not used for 3 weeks before 
the start of the study and oral corticosteroids were 
withdrawn at least 2 months before the study. Patients 
who developed a nasal infection during the 2-week 
period prior to the study were excluded. None of the 
patients had immunotherapy reviously. 
The study was approved by the Medical Ethics Com- 
mittee of the University Hospital Rotterdam-Dijkzigt 
and all patients gave written informed consent. 
2.2. Nasal challenge and lavage 
After the positive skin test the subjects entered the 
double-blind placebo-controlled cross-over phase of the 
study. Each underwent wo allergen challenges, per- 
formed after a twice daily pretreatment with 200 tzg 
fluticasone propionate (aqueous nasal spray (Glaxo, 
UK)) or placebo spray for 2 weeks. A 3-week washout 
period separated the two treatment periods. 
Before nasal challenge with house dust mite extract, 
a nasal lavage was performed 4 times to obtain base- 
line levels and to clear the nose of secretions (b). To 
prevent nasal congestion, 0.25 ml oxymetazoline (0.1%) 
was sprayed into each nostril 5 min before the first 
challenge (prescribed by the Hospital Ethical Commit- 
tee). Nasal lavage was performed as described before 
(Garrelds et al., 1994; Gerth van Wijk et al., 1992; 
Naclerio et al., 1983). Both nostrils were washed with 5 
ml saline, prewarmed to 37°C. Lavage fluid was col- 
lected in plastic tubes and kept on ice. After centrif- 
ugation (10 min, 400 x g) the supernatants of lavage 
fluids were stored at -20°C until determinations. Due 
to the low number of cells in the lavages we were not 
able to count the number of eosinophils and perform 
statistical analysis. To obtain a control challenge (c), 
0.125 ml phosphate-buffered saline (containing 0.03% 
human serum albumin and 0.05% benzalkonium chlo- 
ride) was sprayed in each nostril and a nasal lavage was 
performed. For allergen challenge 0.125 ml allergen 
extract was sprayed in each nostril and 10 min there- 
after a nasal lavage was performed. Allergen doses of 
100, 1000, 10000 (h l -h3)  BU/ml  (extract of D. 
pteronyssinus; ALK, Groningen, Netherlands) were ad- 
ministered. From 30 min up to 9.5 h after the last 
challenge (given at h3) the nasal washings were col- 
lected every hour by washing both nostrils with saline 
(s l -s l0) .  
2.3. Symptom score 
Symptoms were scored to assess the correlation 
between clinical symptoms and interleukin-5 produc- 
tion. The score was compiled before each lavage and 
after phosphate-buffered saline challenge and after 
each allergen spray. Symptom scores were graded in 
points: 3-4  sneezes = 1 point; > 5 sneezes = 3 points; 
rhinorrhoea anterior = 1 point; rhinorrhoea posterior 
= 1 point; difficult nasal breathing = 1 point; one nos- 
tril blocked = 2 points; both nostrils blocked = 3 points; 
pruritus of the nose = 1 point; pruritus of palate or 
ear = 1 point and conjunctivitis = 1 point (total score 
ranged from 0 to 11 points). 
2.4. Interleukin-5 assay 
Material 
Tween 20 (Merck, Darmstadt, Germany); bovine 
serum albumin fraction V (Euromex, Schiltigheim, 
France); horseradish peroxidase-conjugated goat anti- 
rabbit immunoglobulin G (IgG) F(ab') 2 (Biosys, Com- 
pi~gne, France); TMB microwell peroxidase substrate 
system (Kirkegaard & Perry Lab., Gaithersburg, MD, 
USA); polyclonal rabbit anti-human interleukin-5 
(Genzyme, Cambridge, MA, USA); anti-human inter- 
leukin-5 monoclonal antibody and recombinant human 
interleukin-5 were kindly provided by Drs. R. Devos 
and J. Tavernier (Roche, Gent, Belgium). 
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Method 
ELISA plates (96-well Immuno Plate MaxiSorp, 
Nunc, Roskilde, Denmark) were coated with 100/zl of 
the anti-human interleukin-5 monoclonal antibody (1 
/xg/ml in phosphate-buffered saline, pH 7.4) at 37°C 
for 2 h. The wells were washed 5 times with 
phosphate-buffered saline containing 0.1% Tween 20. 
Then, 100 /zl of the sample or recombinant human 
interleukin-5 standard (0.2-200 ng/ml)  in phosphate- 
buffered saline-Tween and 3% bovine serum albumin 
was added to each well and incubated at 37°C for 1 h. 
The wells were washed 3 times with phosphate-buffered 
saline-Tween and incubated with polyclonal rabbit 
anti-human interleukin-5 (10 /zg/ml in phosphate- 
buffered saline-Tween-bovine s rum albumin) at 37°C 
for 1 h. After the wells were washed 3 times with 
phosphate-buffered saline-Tween, horseradish peroxi- 
dase-conjugated goat anti-rabbit IgG F(ab')2, at a dilu- 
tion of 1/4000 in phosphate-buffered saline-Tween- 
bovine serum albumin, was added for 1 h. Then, 100/zl 
of freshly prepared substate solution (TMB microwell 
peroxidase substate) was added to each well. After a 
10-min incubation, the reaction was stopped by the 
addition to each well of 100 /zl of a 2 M solution of 
HC1. Absorbance was read at 450 nm. The lower limit 
of sensitivity of the assay was 0.18 ng/ml.  
2.5. Eosinophil cationic protein assay 
ECP was determined in the lavages by radioim- 
munoassay (Kabi Pharmacia Diagnostics, Uppsala, 
Sweden). 
2.6. Statistical analysis 
Statistical analysis was performed with the Fried- 
man two-way analysis of variance (ANOVA) followed 
by the Wilcoxon matched-pairs signed-ranks test. The 
effect of fluticasone propionate nasal spray on the 
early phase reaction (area under the curve (AUC) 
between hl and sl) and the late phase reaction (AUC: 
between s4 and sl0) was assessed. These areas under 
the curve are based on the outcome of the symptom 
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Fig. 1. Effect of placebo (e) and fluticasone propionate aqueous nasal spray (©) on the symptom scores (A), interleukin-5 levels in nasal lavages 
(B) and eosinophil cationic protein (ECP) levels in nasal lavages (C) of the 11 patients allergic to house dust mite who showed both an early and a 
late phase reaction. Values are expressed as means + S.E.M. Significant differences in comparison to baseline: * P < 0.05. b: baseline, c: 
challenge with phosphate-buffered saline; hl ,  h2 and h3, challenge with 100, 1000 and 10000 BU/ml  house dust mite extract respectively; 
s l - s l0 ,  lavage performed every hour after the challenge with 10000 BU/ml  house dust mite extract at h3. 
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3. Resu l ts  
Eleven patients (out of 24) showed both an early and p 6 
a late phase reaction to the house dust mite extract, as on 
assessed by their symptom scores (Fig. 1A: symptom 
[[ 4 score; B: interleukin-5; and C: ECP), whereas the other 
gl, 
13 patients showed only an early phase reaction (Fig. E 
2). ~" 2 
3.1. Symptom score 
The effects of placebo and fluticasone propionate 
nasal spray on the symptom scores of the 11 patients 
who showed both an early and a late phase reaction to 
the house dust mite with treatment are shown in Fig. 
1A. A significant increase was observed immediately 
after the challenge with house dust mite extract in 
comparison with baseline levels in the placebo group 
(hl -s3;  P < 0.05) and in the fluticasone group (h2 and 
h3; P_< 0.05). A late phase reaction occurred only in 
the placebo group, when symptoms recurred (s6-s9; 
P < 0.05). The symptom score of patients treated with 
fluticasone propionate nasal spray was significantly 
lower than that of the placebo group in the early phase 
reaction (AUC h l - s l ;  P_< 0.05) as well as in the late 
phase reaction (AUC s4-sl0; P _< 0.05). 
The results of the 13 patients who showed only an 
early phase reaction are shown in Fig. 2. A significant 
increase was observed immediately after the challenge 
with house dust mite extract in comparison with the 
baseline levels in the placebo group (h l - s l ;  P_< 0.05) 
and in the fluticasone group (pbs-s3; P < 0.05). No 
late phase reaction occurred. The symptom score of 
patients treated with fluticasone propionate nasal spray 
was significantly lower than that of the placebo group 
in the early phase reaction (AUC h l - s l ;  P _< 0.05). 
3.2. Nasal interleukin-5 release 
The effects of placebo and fluticasone propionate 
nasal spray on the levels of interleukin-5 in nasal 
washings from the 11 patients with both an early and a 
late phase allergic reaction to house dust mite are 
presented in Fig. lB. Interleukin-5 levels varied be- 
tween 50 and 100 pg /ml  before provocation, with a 
tendency towards an increase in comparison with the 
baseline level in the placebo group (h2; P = 0.0702), a 
tendency which was not seen in the fluticasone propi- 
onate group. During the late phase reaction inter- 
leukin-5 was released again in the placebo group. Fluti- 
casone propionate nasal spray significantly inhibited 
the release of interleukin-5 in the late phase reaction 
in comparison with placebo (AUC s4-sl0; P < 0.05). 
The 13 patients with only an early phase allergic 
reaction to house dust mite who were treated with 
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Fig. 2. Effect of placebo (e) and f lut icasone propionate aqueous 
nasal spray (©) on the symptom scores, and interleukin-5 and 
eosinophi l  cationic protein levels in nasal lavages of the 13 al lergic 
pat ients to house dust mite who showed only an early phase reaction. 
Values are expressed as means _+ S.E.M. Significant differences in
comparison to baseline: *P_< 0.05. b: baseline, c: challenge with 
phosphate-buffered saline; hl, h2 and h3, challenge with 100, 1000 
and 10000 BU/ml house dust mite extract respectively; sl-sl0, 
lavages performed every hour after the challenge with 10000 BU/ml 
house dust mite extract at h3. 
placebo or fluticasone propionate nasal spray showed 
neither an immediate nor a late phase release of inter- 
leukin-5 (Fig. 2). 
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3.3. Eosinophil cationic protein 
The effects of placebo and fluticasone propionate 
nasal spray on the ECP levels of the 11 patients who 
showed both an early and a late phase reaction to 
house dust mite are shown in Fig. 1C. A significant 
increase in ECP was observed in comparison with the 
baseline levels during the late phase reaction (s7-sl0; 
P < 0.05). The ECP level in nasal lavages was signifi- 
cantly decreased by treatment with fluticasone propi- 
onate nasal spray in comparison with those of the 
placebo during the late phase (AUC s4-sl0; P < 0.05) 
(De Graaf-in 't Veld et al., 1995). 
The 13 patients with only an early phase allergic 
reaction to house dust mite did not show a late phase 
release of ECP (all levels were below 10 ng/ml;  Fig. 2) 
after placebo or fluticasone propionate. 
4. Discussion 
This is the first study demonstrating that inter- 
leukin-5 is present in detectable amounts in nasal 
lavage obtained from patients allergic to house dust 
mites who show both an early and late phase reaction. 
Nasal challenge with house dust mite extract immedi- 
ately caused nasal symptoms and tended to increase 
levels of interleukin-5 in the placebo group in the early 
phase reaction. Nasal challenge with phosphate- 
buffered saline also caused an immediate increase in 
the level of interleukin-5 in the placebo group, which 
may indicate a nonspecific reaction due to the human 
serum albumin in the phosphate-buffered saline. Be- 
tween 3.5 and 8.5 h after the challenge with house dust 
mite extract symptoms recurred and interleukin-5 lev- 
els increased, reflecting a late phase reaction. 
Interleukin-5 was released in the lungs of rhinitis 
patients allergic to ragweed 24 h after segmental anti- 
gen challenge, and this release correlated with 
eosinophil recruitment, degranulation, and lung injury 
(Ohnishi et al., 1993). In inferior turbinate biopsies 
from patients with perennial allergic rhinitis inter- 
leukin-4 and interleukin-5 were localized by immuno- 
histochemical staining of mast cells and interleukin-5 
immunoreactivity was also localized in eosinophils. No 
immunoreactivity for cytokines was found in T cells 
(Bradding et al., 1993). In studies with grass pollen- 
sensitive patients 24 h after local provocation with 
antigen, nasal biopsies showed an increase in cells with 
positive mRNA hybridization signals for interleukin-3, 
interleukin-4, GM-CSF and interleukin-5 (Durham et 
al., 1992) when allergen-challenged sites were com- 
pared with control sites. It has been recently demon- 
strated by Terada et al. that interleukin-5 is released in 
nasal fluid in the late phase reaction after challenge 
with Japanese cedar (Terada et al., 1994). 
In this study we demonstrated that ECP was re- 
leased a few hours later (between 6.5 and 9.5 h) than 
interleukin-5 (between 3.5 and 8.5 h), which may indi- 
cate that the number of eosinophils was increased 
and/or  that the eosinophils present were more acti- 
vated during the late allergic reaction. Due to the low 
numbers of cells in the lavages we were not able to 
perform statistical analysis of eosinophil numbers. 
Our study showed a significant decrease in inter- 
leukin-5 and ECP levels during the late phase reaction 
after treatment with fluticasone propionate nasal spray. 
This decrease correlated with an improved symptom 
score in the 11 patients with an early and late phase 
reaction. A decreased release of ECP may indicate that 
the number of eosinophils was decreased and/or  that 
the eosinophils were less active during the late allergic 
reaction after treatment with fluticasone propionate 
nasal spray. The protective ffects of fluticasone propi- 
onate nasal spray on interleukin-5 were detected in the 
late phase reaction and failed to affect the initial 
(baseline) release of interleukin-5 as well as the early 
phase response to house dust mite provocation. Other 
factors involved in allergic rhinitis, such as albumin, 
tryptase, leukotriene E4, prostaglandin D 2 and platelet 
activating factor, are also increased after house dust 
mite provocation and are inhibited by fluticasone pro- 
pionate nasal spray (Garrelds et al., 1994; De Graaf-in 
't Veld et al., 1995). 
Pretreatment with fluticasone propionate nasal spray 
improved the symptom score of patients with seasonal 
allergic rhinitis after nasal challenge with allergen and 
decreases the number of nasal eosinophils, basophils 
and neutrophils (Juliusson et al., 1993). It has been 
proposed that fluticasone propionate nasal spray may 
act by preventing the activation of these cells and the 
subsequent release of (chemotactic) inflammatory me- 
diators and further influx of cells. Several in vitro 
studies have shown that corticosteroids inhibit T cell 
proliferation and cytokine production (Culpepper and 
Lee, 1985), decrease the number of cells expressing 
interleukin-4 and interleukin-5 mRNA in vivo (Robin- 
son et al., 1993) and decrease the number and activa- 
tion of mast cells and eosinophils in bronchial biopsies 
and lavages (Djukanovic et al., 1992). 
In summary, the results of this study show that 
interleukin-5 was found in detectable amounts in nasal 
lavages of patients with a house dust mite allergy 
before and after challenge with house dust mite ex- 
tract, which caused immediately nasal symptoms. Be- 
tween 3.5 and 8.5 h after the last challenge symptoms 
recurred and interleukin-5 levels increased, reflecting a
late phase reaction. ECP was released between 6.5 and 
9.5 h after challenge. A 2-week pretreatment with 200 
/~g fluticasone propionate aquous nasal spray resulted 
in a significant decrease in interleukin-5 and ECP 
levels in the late phase reaction. This decrease was 
correlated with an improved symptom score. 
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Al though it is not  ful ly unders tood  how the  mecha-  
n i sm of  in ter leuk in -5  re lease  is modu la ted ,  the  pro-  
g rammed re lease  of  th is  cy tok ine  wou ld  be  of  in teres t  
in o ther  a l lerg ic  react ions .  
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